Fractyl Health, Inc
Fractyl Health is a U.S.-based metabolic therapeutics company developing device and gene-therapy approaches for obesity and type 2 diabetes. Its lead platform, Revita, is an endoscopic duodenal mucosal resurfacing procedure designed to modify disease biology, while its Rejuva program explores pancreas-targeted gene therapy for longer-duration metabolic treatment.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2023–2025
Liiketoiminta
Osuus liikevaihdostaEndoscopic duodenal mucosal resurfacing procedure and related disposable components used to treat metabolic disease.
Preclinical and clinical gene-therapy candidates intended to address the root causes of obesity and T2D.
Pivotal studies, registries, and follow-up programs that generate evidence for regulatory and payer adoption.
Sales, marketing, medical affairs, distribution, and manufacturing capabilities being built for future launch.
Asiakkaat
Fractyl does not yet have approved commercial products in the U.S., so its near-term customers are clinical investigators, physicians, and study sites involved in its trials and registries. If approved, its end customers would be diabetologists, endocrinologists, gastroenterologists, interventional endoscopists, hospitals, and payors evaluating the clinical and economic value of Revita and, later, Rejuva-based therapies.
Diabetologists, endocrinologists, PCPs, gastroenterologists, and endoscopists who would use or refer patients for Revita because it offers a disease-modifying approach.
Facilities that would buy the procedure workflow, disposables, and related support if the therapy is commercialized.
Commercial and public payors that determine reimbursement and therefore adoption economics for Revita.
Research centers enrolling patients in REMAIN, REVEAL-1, and registry studies to validate safety and efficacy.
Strategia
Fractyl’s strategy is to complete clinical development, secure regulatory approvals, and build the commercial infrastructure needed to launch Revita and later Rejuva. The company is also trying to validate a consumables-based model and generate payer acceptance by showing durable clinical benefit and favorable procedure economics.
Regulatory approval and physician adoption depend on robust safety and efficacy data.
The company needs sales, marketing, medical affairs, and distribution capabilities before launch.
Coverage decisions will determine whether Revita can scale economically after approval.
Management expects future revenue streams to depend on repeat procedure economics and consumable usage.
Maantiede
Fractyl is headquartered in the United States and currently has no approved product sales there. The company’s disclosed clinical evidence includes a Germany real-world registry study, indicating some operational and data-generation exposure outside the U.S., but the business remains overwhelmingly U.S.-centric at this stage.
Riskit
Fractyl is a development-stage company with no approved U.S. products, so its business depends on successful clinical outcomes, regulatory clearance, and future reimbursement. It also faces financing, manufacturing-supply, and commercialization execution risk, while competing against larger medical device, diabetes, and biopharma companies with stronger resources and established channels.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea
The company has not completed pivotal studies, so adverse data could prevent approval and commercialization.
Kohdistuu - Financing and going-concern pressureVaikutus: KorkeaTodennäköisyys: Korkea
The company expects continued operating losses and negative cash flow until product sales begin, requiring additional capital.
Kohdistuu - Reimbursement and payer adoption riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Even with approval, payors may require more evidence or decline coverage, limiting uptake.
Kohdistuu: Coverage for Revita DMR procedure
- Manufacturing and supply-chain dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Key components and sterilization are outsourced, and some materials are single-sourced, which can disrupt trials or launch.
Kohdistuu: Revita disposables and Rejuva materials
- Competitive pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Larger competitors may offer safer, cheaper, or more established alternatives and can outspend Fractyl on commercialization.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätManagement says critical accounting estimates related to warrant liabilities were updated, implying fair-value judgments can move earnings.
Vaikutus: Can create non-cash gains or losses in the income statement
Trial, preclinical, and manufacturing services are contracted externally and require estimate-based accruals.
Vaikutus: Affects R&D expense timing and comparability
As a public development-stage company, equity awards are likely a meaningful operating expense.
Vaikutus: Raises reported operating costs without immediate cash outflow
The company expects additional funding needs and ongoing losses until commercialization.
Vaikutus: Shapes balance-sheet and cash-flow interpretation
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Rezolute, Inc.
RZLT · Pharmaceutical Preparations
Rhythm Pharmaceuticals, Inc
RYTM · Pharmaceutical Preparations
Rhythm Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for rare genetic disorders of obesity and related metabolic diseases.
ENDRA Life Sciences Inc.
NDRA · Electromedical & Electrotherapeutic Apparatus
Reviva Pharmaceuticals Holdings, Inc.
RVPH · Pharmaceutical Preparations
Glucotrack, Inc.
GCTK · Surgical & Medical Instruments & Apparatus
Madrigal Pharmaceuticals, Inc
MDGL · Pharmaceutical Preparations
Madrigal Pharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company focused on developing and selling therapies for metabolic dysfunction-associated steatohepatitis (MASH).
Päivitetty: 24.9.2026